Opinion|Videos|February 6, 2024
Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations
Vinay Raja, MD, explores the management of patients with Stage-III disease and actionable EGFR/ALK aberrations, as well as the treatment approach for patients with PD-L1 <1%.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy
4
Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
5